ga

Skip to content

My Files [0]

These are the files you have added to your collection.

  • You don't have any documents yet, feel free to browse the website and add documents.
Top

News for 2005

The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent agency funded by Canadian federal, provincial, and territorial governments to provide health care decision makers with credible, impartial advice and information about the effectiveness and efficiency of drugs and other health technologies. Unlike regulators who determine which technologies can be used in Canada, CADTH supports decision makers who are exploring what technologies should be used to achieve the best outcomes both on patient health and the health care system.

For details on how to contact CADTH, visit our Contact Us page.

CCOHTA Announces the Winners of the MPUP Fall Draw

December 09, 2005

Congratulations to the Winners of the MPUP Fall Draw!First Prize ($125 Online Bookstore Gift Certificate): Dr. Anne NguyenProject: BC Community Drug Utilization ProgramSecond Prize ($100 Online ...

CCOHTA Releases Multi Year Business Plan

November 22, 2005

CCOHTA’s annual business plan establishes strategic priorities and outlines the key initiatives CCOHTA will undertake to achieve these priorities. CCOHTA’s Board of Directors approves ...

CDR Evaluation and CCOHTA Response to Recommendations Released

October 12, 2005

OTTAWA — An independent evaluation of the Common Drug Review conducted by EKOS Research Associates was released today by the Canadian Coordinating Office for Health Technology Assessment ...

CCOHTA awards $1.6 million for HTA Capacity Building Grants

March 31, 2005

OTTAWA — The Canadian Coordinating Office for Health Technology Assessment ( CCOHTA ) has awarded $1.6 million in grants to support innovative projects that will build capacity to conduct ...

Jury still out on the cost-effectiveness of drug eluting stents

March 01, 2005

OTTAWA — The universal adoption of drug eluting stents over bare metal stents would require significant additional health care funding, even when reductions in repeat revascularization ...